Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xenetic Biosciences Inc (XBIO)

Xenetic Biosciences Inc (XBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,590
  • Shares Outstanding, K 2,291
  • Annual Sales, $ 2,500 K
  • Annual Income, $ -3,960 K
  • EBIT $ -3 M
  • EBITDA $ -3 M
  • 60-Month Beta 2.40
  • Price/Sales 2.22
  • Price/Cash Flow N/A
  • Price/Book 0.94

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.29 +6.60%
on 11/20/25
2.72 -10.32%
on 11/28/25
-0.20 (-7.58%)
since 11/12/25
3-Month
2.29 +6.60%
on 11/20/25
13.93 -82.48%
on 10/08/25
-1.16 (-32.22%)
since 09/12/25
52-Week
2.20 +10.91%
on 04/07/25
13.93 -82.48%
on 10/08/25
-1.76 (-41.90%)
since 12/12/24

Most Recent Stories

More News
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Adjourns 2025 Annual Meeting of Stockholders

XBIO : 2.44 (+0.83%)
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology...

XBIO : 2.44 (+0.83%)
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners

XBIO : 2.44 (+0.83%)
Xenetic Biosciences: Q3 Earnings Snapshot

Xenetic Biosciences: Q3 Earnings Snapshot

XBIO : 2.44 (+0.83%)
Xenetic Biosciences Announces Public Offering Pricing

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Xenetic Biosciences...

XBIO : 2.44 (+0.83%)
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

FRAMINGHAM, MA / ACCESS Newswire / October 10, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies...

XBIO : 2.44 (+0.83%)
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies

XBIO : 2.44 (+0.83%)
Xenetic Biosciences: Q2 Earnings Snapshot

Xenetic Biosciences: Q2 Earnings Snapshot

XBIO : 2.44 (+0.83%)
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center

XBIO : 2.44 (+0.83%)
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date

XBIO : 2.44 (+0.83%)

Business Summary

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an...

See More

Key Turning Points

3rd Resistance Point 2.63
2nd Resistance Point 2.58
1st Resistance Point 2.51
Last Price 2.44
1st Support Level 2.39
2nd Support Level 2.34
3rd Support Level 2.27

See More

52-Week High 13.93
Fibonacci 61.8% 9.45
Fibonacci 50% 8.07
Fibonacci 38.2% 6.68
Last Price 2.44
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar